CD40L Adjuvanted Clade C DNA and MVA HIV Vaccines -Administrative Core

CD40L 佐剂 C 分支 DNA 和 MVA HIV 疫苗 - 管理核心

基本信息

批准号：
9023411
负责人：
Rama Rao Amara
金额：
$ 21.24万
依托单位：
EMORY UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
资助国家：
美国
起止时间：
至
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/9023411
关键词：
AIDS Vaccines Adjuvant Africa South of the Sahara Annual Reports Antibodies Antigens Asia B-Lymphocytes Budgets Cellular Immunity Centers for Disease Control and Prevention (U.S.)Clinical Trials Consultations DNA DNA Vaccines Data Analyses Dendritic Cells Developing Countries Development Ensure Epidemic Genes Genetic Goals HIV HIV Vaccine Trials Network HIV vaccine HIV-1 Health Priorities Human Humoral Immunities Immune Immunization Individual Infection Intellectual Property International AIDS Leadership Legal patent Louisiana Macaca Macaca mulatta Mediation Modeling Morbidity - disease rate Mosses Phase Proteins Publications Publishing Recombinants Research Institute Resources SIV SIV Vaccines Scientist Serinus Surface TNFSF5 gene Thailand United States National Institutes of Health Universities Vaccination Vaccines Viral Viral Vector Virus Virus Diseases data management data sharing efficacy trial global health meetings mortality novel novel strategies preclinical trial prevent programs response stem success vaccination strategy vector vector vaccine

项目摘要

Human immunodeficiency virus (HIV)-l infection is a leading cause of morbidity and mortality around the world, with many new infections occurring daily and the development of a safe and effective HIV vaccine is a critically important global health priority. An effective vaccine for HIV remains elusive and the development of an effective vaccine against HIV is the long-term solution to this problem. The success of the RV144 Thai HIV-1 efficacy trail showing 31% of efficacy has given hope that indeed a protective HIV vaccine can be developed. The goal of this program is to generate novel vaccination approaches that enhance the quantity as well as quality of anti-viral cellular and humoral responses using CD40L as an adjuvant and MVA delta4 as a boosting vector. The overall goal of this administrative core is to provide coordination between projects 1, 2 and 3, and core B, and help with data management and data analyses. This Administrative Core has the following six specific aims: (1) Provide overall coordination for the Program.. (2) Provide data management and statistical support. (3) Provide logistical support for intellectual property filings and negotiations. (4) Assist with publications. (5) Maintain budgets and fiscal oversight. (6) Provide the interface with the HVTN.

人类免疫缺陷病毒（HIV）-L感染是周围发病和死亡率的主要原因世界，每天都会发生许多新感染，而安全有效的艾滋病毒疫苗的发展是至关重要的全球健康优先事项。艾滋病毒的有效疫苗仍然难以捉摸，发展对艾滋病毒的有效疫苗是解决此问题的长期解决方案。 RV144泰国HIV-1的成功有效性的疗效轨迹显示了31％的疗效，希望确实可以开发出一种保护性艾滋病毒疫苗。这该计划的目标是生成新颖的疫苗接种方法，以提高数量和质量使用CD40L作为佐剂和MVA Delta4作为增强载体的抗病毒细胞和体液反应。该行政核心的总体目标是提供项目1、2和3和核心B之间的协调并帮助数据管理和数据分析。该行政核心具有以下六个具体目标：（1）为该计划提供总体协调。（2）提供数据管理和统计支持。（3）为知识产权档案和谈判提供后勤支持。（4）协助出版物。（5）维护预算和财政监督。（6）提供与HVTN的接口。